Last reviewed · How we verify

Formoterol Aldo

Fundacio Privada Mon Clinic Barcelona · FDA-approved active Small molecule

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).

At a glance

Generic nameFormoterol Aldo
Also known asLABA
SponsorFundacio Privada Mon Clinic Barcelona
Drug classLong-acting beta-2 agonist (LABA)
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. Its long-acting formulation provides sustained bronchodilation for 12 hours or more, making it suitable for maintenance therapy in chronic obstructive airway diseases. It is commonly combined with inhaled corticosteroids for enhanced anti-inflammatory and bronchodilatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: